Aimmune Therapeutics (NASDAQ:AIMT) Rating Increased to Buy at Zacks Investment Research

Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The firm currently has a $22.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 10.00% from the company’s previous close.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

Several other analysts also recently issued reports on the company. Wedbush lowered their price target on Aimmune Therapeutics from $80.00 to $76.00 and set an “outperform” rating for the company in a report on Tuesday, March 19th. BidaskClub downgraded Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 23rd. Cantor Fitzgerald set a $45.00 price target on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, Credit Suisse Group started coverage on Aimmune Therapeutics in a report on Tuesday, May 21st. They issued an “outperform” rating and a $30.00 price target for the company. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $46.43.

AIMT stock opened at $20.00 on Thursday. The firm has a market cap of $1.26 billion, a PE ratio of -5.45 and a beta of -0.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.65 and a quick ratio of 7.65. Aimmune Therapeutics has a 52 week low of $19.25 and a 52 week high of $36.12.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.07. On average, analysts forecast that Aimmune Therapeutics will post -3.77 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in AIMT. FMR LLC increased its holdings in Aimmune Therapeutics by 30.3% in the 1st quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock valued at $61,117,000 after purchasing an additional 635,362 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of Aimmune Therapeutics during the first quarter valued at about $11,414,000. Bank of New York Mellon Corp grew its stake in shares of Aimmune Therapeutics by 223.4% during the fourth quarter. Bank of New York Mellon Corp now owns 553,206 shares of the biotechnology company’s stock valued at $13,233,000 after acquiring an additional 382,154 shares in the last quarter. Norges Bank acquired a new stake in shares of Aimmune Therapeutics during the fourth quarter valued at about $6,035,000. Finally, Victory Capital Management Inc. grew its stake in shares of Aimmune Therapeutics by 33.9% during the fourth quarter. Victory Capital Management Inc. now owns 950,061 shares of the biotechnology company’s stock valued at $22,726,000 after acquiring an additional 240,310 shares in the last quarter. Hedge funds and other institutional investors own 76.13% of the company’s stock.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Story: What is the definition of a trade war?

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.